Alacrita brings together a world-class network of over 350 pharmaceutical consultants, each highly skilled in their specialty area and hand-picked by us over the past 15 years. We've carefully curated our network to ensure we're providing our clients with only the highest-caliber of expertise available.
Our core team of partners form the keystone of every consulting project. Each brings at least 20 years of pharmaceutical industry experience, along with deep domain knowledge, senior business expertise and executive-level skillsets. Alacrita core partners & consultants leverage our consulting network, creating a combination that allows us to support clients at each stage of their project or company, with expertise that is precisely targeted to their specific need.
Our consultants have led programs discovering, developing, manufacturing, and commercializing drug products, bringing the practical insight and execution expertise that only come from having done the work themselves.
For more than fifteen years, we've helped life-science organizations solve complex scientific and operational challenges, make critical business and investment decisions, strengthen leadership capacity, and advance their programs with the rigor and judgment of experienced industry professionals.
We provide specialized consulting across three core areas.
Our expert teams are ready to support you through every step of product development, making sure you maximize value at each stage.
Gauge and rank the opportunities for your R&D programs or technology platforms to deliver value, by framing the commercial potential and charting the path to market.
Learn moreFor any early-stage development needs, Alacrita's preclinical team is well-equipped to support you with strategic, technical and regulatory expertise.
Learn moreLeverage the skills and experience of our seasoned drug development physicians to refine your clinical strategy and operations.
Learn moreDe-risk your regulatory interactions by tapping into our deep expertise in navigating US and EU agency regulations, submissions and responses.
Learn moreAlacrita's pharmaceutical development, CMC-regulatory, QA and supply chain experts can help you chart the most efficient course through product development.
Learn moreFrom company formation to Phase II clinical trials, we orchestrate the strategic expertise that transforms biotech concepts into fundable realities. Your vision, our experience, integrated execution. Your roadmap to funded, executable progress.
A sound strategy is essential to healthcare investors at all stages of corporate development.
Learn moreHelping you advance programs by providing seasoned operators ready to step in, when you're not in position to permanently hire.
Learn moreStrategic guidance for platform technology developers making critical decisions about partnerships, business models, indication prioritization and regulatory pathways.
Learn moreFor biotechs considering the "go-it-alone" approach, we provide strategic mapping of budget, resources, and activities required to commercialize a pipeline product, informing critical decisions during early clinical stages.
Learn moreWe dovetail with your in-house business development team to help find, evaluate and assess new assets, even taking responsibility for out-licensing your products to a pharma partner.
We help companies and investors find new opportunities, working alongside a client's team to maximize their effectiveness.
Learn moreWe work closely with our clients, using the breadth and depth of our consulting talent to undertake all aspects of due diligence.
Learn moreOur expert teams develop in-depth valuation models for our clients, helping inform strategic decision-making and investments.
Learn moreWe use a tailored approach to support in- and out-licensing needs, advising clients on both sides of the table.
Learn moreStrategic, scientific, and operational expertise to support life science investors, guide biotech fundraising, and accelerate value across the investment lifecycle.
Alacrita provides hands-on advisory and execution support to life science investors, their portfolio companies, and directly to early-stage biotechs. Our consultants bring deep scientific, strategic, and operational expertise—from due diligence and opportunity assessment to post-investment execution, fundraising strategy, and investor communications.
We help biotech teams prepare for financing, sharpen value positioning, and deliver on development milestones, while giving investors the insight, clarity, and bandwidth needed to guide value creation.
Alacrita supports biotech companies through both the fundraising process and the critical post-investment execution phase, delivering integrated strategic, technical, and operational expertise to maximize value at each milestone.
Learn moreAlacrita partners with venture firms to strengthen investment decisions and support portfolio company execution. Whether evaluating an opportunity, supporting the formation of a new biotech, or helping a team deliver on key development milestones, we provide flexible, high-caliber consulting across core functions.
Learn moreWe work alongside in-house IR teams, executive leadership, and IR firms to supplement communications efforts with scientific and strategic depth—helping biotech companies build credibility and prepare for meaningful investor engagement.
Learn moreWhether your dispute regards royalty payments or the technical aspects of a patent, our qualified consultants can collaborate with your legal team and provide expert reports and testimony.
Alacrita's core team and extensive network of independent, specialist consultants allows us to provide law firms with expert witnesses who have the precise technical or commercial expertise required for the needs of their case. These individuals are full-time consultants, typically bringing 25+ years of experience in their respective fields, and often specialize in specific therapy areas and product modalities.
Real-world examples of how our life science consulting expertise has helped clients achieve their objectives.
Contact us to discuss how our experienced life science consultants can support your development goals.
Challenge: A pharma company developing a first-in-class therapeutic to treat rare paediatric neurodegenerative disorders was nearing NDA approval in multiple indications and was ready to initiate fund raising activities to support its next steps. Alacrita had previously been commissioned by an investor to conduct due diligence on the company for an earlier funding round. This time, we were approached directly by the pharma company to perform an updated due diligence exercise and develop an independent report of the company’s progress for other potential investors.
Solution: Our neurology expert reviewed all of the available clinical data for the company’s lead product and developed an opinion on the strength of the data and the likelihood of approval in each indication. Using these outputs, our market analysis expert quantified the commercial potential in each indication. We presented our findings to the pharma company, which subsequently used the output of the due diligence to engage with potential investors.
Challenge: A midsize speciality pharmaceuticals company has retained Alacrita to conduct a series of due diligence assessments to support its business development function. The client focuses on a particular area defined as disorders of one of the major organ systems and has been very active in licensing and M&A over the past four years.
Solution: The client established a framework agreement with Alacrita facilitating the commissioning of a series of due diligence assignments over the course of each year. The typical process involves Alacrita identifying appropriately qualified experts from its network for each DD situation who then interact with the relevant members of the client's internal team. Over the course of any particular year, Alacrita conducts three to five assessments for the client, ranging in size depending on the development stage of the target asset(s).
Challenge: A European clinical-stage pharma company was developing a recombinant protein for multiple immune-driven indications and required support in shaping its future business strategy. Alacrita was commissioned to conduct an independent strategic review of the company, identify any short and long-term value-adding activities for its programs and identify potential future pharma partners.
Solution: Alacrita´s specialist team conducted a reality check on the target company´s activities to date, analyzing the biological target robustness across different indications, proof of concept data from each program and the current valuation assumptions.
From this we identified several activities and direction changes that could add immediate value to the company and improve attractiveness to future pharma partners.
Speak with us about our pharma & biotech consulting services.
Alacrita Consulting, Limited
UK, Europe & Asia
2 Royal College St
London, UK
NW1 0NH
Registered in England & Wales.
No. 10530608
Alacrita Consulting, Inc.
US
One Broadway
Floor 14
Cambridge, MA 02142
Registered in Delaware
© 2009 - 2025 Alacrita Holdings Limited
